CY2503B1 - Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate. - Google Patents

Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.

Info

Publication number: CY2503B1
Authority: CY; Cyprus
Prior art keywords: fluoxetine; transdermal administration; acetate; composition; maleate
Prior art date: 1996-07-15

Application number

CY0500016A

Other languages

English (en)

Inventor

Robert M Gale

Melinda K Nelson

Michel J N Cormier

Suneel K Gupta

Patricia S Campbell

Original Assignee

Alza Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-15

Filing date

2005-03-04

Publication date

2005-09-02

2005-03-04 Application filed by Alza Corp filed Critical Alza Corp

2005-09-02 Publication of CY2503B1 publication Critical patent/CY2503B1/xx

Links

RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 title abstract 11
229960002464 fluoxetine Drugs 0.000 title abstract 11
239000000203 mixture Substances 0.000 title abstract 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title abstract 2
238000009472 formulation Methods 0.000 title 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
239000003623 enhancer Substances 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
239000012528 membrane Substances 0.000 abstract 2
206010040880 Skin irritation Diseases 0.000 abstract 1
239000003246 corticosteroid Substances 0.000 abstract 1
238000012377 drug delivery Methods 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000003961 penetration enhancing agent Substances 0.000 abstract 1
230000036556 skin irritation Effects 0.000 abstract 1
231100000475 skin irritation Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CY0500016A 1996-07-15 2005-03-04 Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate. CY2503B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2172796P	1996-07-15	1996-07-15

Publications (1)

Publication Number	Publication Date
CY2503B1 true CY2503B1 (en)	2005-09-02

Family

ID=32848735

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY0500016A CY2503B1 (en)	1996-07-15	2005-03-04	Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.

Country Status (7)

Country	Link
EP (1)	EP0946184B1 (de)
AT (2)	ATE277620T1 (de)
AU (1)	AU3601897A (de)
CY (1)	CY2503B1 (de)
DE (2)	DE69730988T2 (de)
ES (2)	ES2259746T3 (de)
WO (1)	WO1998002169A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030013740A1 (en) *	1998-03-27	2003-01-16	Martin P. Redmon	Stable dosage forms of fluoxetine and its enantiomers
EP1152749B1 (de) †	1999-02-08	2006-04-12	ALZA Corporation	Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden
US7258869B1 (en)	1999-02-08	2007-08-21	Alza Corporation	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7005138B2 (en) *	2001-12-21	2006-02-28	Duramed Pharmaceuticals, Inc.	Method of systematically delivering SSRIs
BR0314713A (pt) *	2002-09-24	2005-07-26	Combinatorx Inc	Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
US20080044462A1 (en) *	2006-04-06	2008-02-21	Collegium Pharmaceutical, Inc. Delaware	Stabilized transdermal bupropion preparations
MX2008014870A (es)	2006-05-30	2009-02-12	Intarcia Therapeutics Inc	Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (de)	2006-08-09	2012-11-14	Intarcia Therapeutics, Inc.	Osmotische freisetzungssysteme und kolbenanordnungen
HRP20130259T1 (hr)	2007-04-23	2013-04-30	Intarcia Therapeutics, Inc.	Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
DK2240155T3 (da)	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
SMT201700583T1 (it)	2009-09-28	2018-01-11	Intarcia Therapeutics Inc	Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en)	2015-06-03	2021-02-23	Intarcia Therapeutics, Inc.	Implant placement and removal systems
RU2760007C2 (ru)	2016-05-16	2021-11-22	Интарсия Терапьютикс, Инк.	Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
CN110225762A (zh)	2017-01-03	2019-09-10	因塔西亚制药公司	包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5411738A (en) *	1989-03-17	1995-05-02	Hind Health Care, Inc.	Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5589511A (en) *	1990-08-13	1996-12-31	Sepracor Inc.	Method for treating migraine headaches using optically pure S(+) fluoxetine
JPH06507416A (ja) *	1991-05-07	1994-08-25	ダイナジェン・インコーポレーテッド	禁煙のための調節された持続的放出伝達システム
DE4301783C1 (de) *	1993-01-23	1994-02-03	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
AU6410494A (en) *	1993-03-17	1994-10-11	Alza Corporation	Device for the transdermal administration of alprazolam
US5601839A (en) *	1995-04-26	1997-02-11	Theratech, Inc.	Triacetin as a penetration enhancer for transdermal delivery of a basic drug
AU7113996A (en) *	1995-09-22	1997-04-09	Eli Lilly And Company	Methods of treating beta-amyloid-associated conditions

1997
- 1997-07-15 AU AU36018/97A patent/AU3601897A/en not_active Abandoned
- 1997-07-15 ES ES03022248T patent/ES2259746T3/es not_active Expired - Lifetime
- 1997-07-15 EP EP97932610A patent/EP0946184B1/de not_active Expired - Lifetime
- 1997-07-15 WO PCT/US1997/012335 patent/WO1998002169A2/en not_active Ceased
- 1997-07-15 ES ES97932610T patent/ES2227707T3/es not_active Expired - Lifetime
- 1997-07-15 AT AT97932610T patent/ATE277620T1/de not_active IP Right Cessation
- 1997-07-15 DE DE69730988T patent/DE69730988T2/de not_active Expired - Fee Related
- 1997-07-15 DE DE69735656T patent/DE69735656T2/de not_active Expired - Fee Related
- 1997-07-15 AT AT03022248T patent/ATE322272T1/de not_active IP Right Cessation
2005
- 2005-03-04 CY CY0500016A patent/CY2503B1/xx unknown

Also Published As

Publication number	Publication date
HK1063148A1 (en)	2004-12-17
ATE277620T1 (de)	2004-10-15
ES2259746T3 (es)	2006-10-16
WO1998002169A2 (en)	1998-01-22
DE69730988D1 (de)	2004-11-04
WO1998002169A3 (en)	1998-03-12
DE69735656D1 (de)	2006-05-18
EP0946184B1 (de)	2004-09-29
DE69730988T2 (de)	2006-02-23
ATE322272T1 (de)	2006-04-15
AU3601897A (en)	1998-02-09
DE69735656T2 (de)	2006-08-24
ES2227707T3 (es)	2005-04-01
EP0946184A2 (de)	1999-10-06

Similar Documents

Publication	Publication Date	Title
CY2503B1 (en)	2005-09-02	Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
GB2316004B (en)	1999-08-04	Novel formulations for transdermal delivery of pergolide
US4746515A (en)	1988-05-24	Skin permeation enhancer compositions using glycerol monolaurate
US5686097A (en)	1997-11-11	Monoglyceride/lactate ester permeation enhancer for codelivery of steroids
US4568343A (en)	1986-02-04	Skin permeation enhancer compositions
MX9709162A (es)	1998-03-31	Composiciones mejoradas de la permeacion en la piel que usan lactilatos de acilo.
US5000956A (en)	1991-03-19	Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
NO944249L (no)	1994-11-14	Transdermal administrering av oksybutynin
AU4990797A (en)	1998-05-15	Permeation enhancers for transdermal drug delivery compositions, devices, and methods
TW366286B (en)	1999-08-11	Flavour-masked pharmaceutical compositions
KR900701274A (ko)	1990-12-01	남용 가능성을 감소시킨 용량 제형
EP0857488A1 (de)	1998-05-20	Verfahren und Zusammensetzungen zur Erhöhung des Hautdurchtritts von Arzneistoffen unter Verwendung von Permeationsbeschleunigern
EP0857488A3 (de)	1999-08-25	Verfahren und Zusammensetzungen zur Erhöhung des Hautdurchtritts von Arzneistoffen unter Verwendung von Permeationsbeschleunigern
GR3032523T3 (en)	2000-05-31	Therapeutic preparation for the transdermal administration of active substances
DE69521688D1 (de)	2001-08-16	Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
MY111260A (en)	1999-10-30	Pharmaceutical composition for the treatment of nicotine dependence
WO2001030802A3 (en)	2002-02-14	Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
AU2313297A (en)	1997-11-12	Transdermally administered dextromethorphan as antitussive agent
CA2202397A1 (en)	1996-04-25	Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
US5077054A (en)	1991-12-31	Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
JPH0640947A (ja)	1994-02-15	経皮吸収製剤用組成物および経皮吸収製剤
ES2184561A1 (es)	2003-04-01	Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
CA2333076A1 (en)	1999-11-25	Topical application of muscarinic analgesic drugs such as neostigmine
AU5105699A (en)	2000-02-14	Formulations for the transdermal administration of fenoldopam
AU1305999A (en)	1999-06-07	(+)-ephedrine as a sympathomimetic drug